Navigation Links
Inostics DNA Blood Test Provides a More Precise Picture of Resistance Mutations Than Traditional Biopsies
Date:4/9/2013

BALTIMORE and HAMBURG, Germany, April 9, 2013 /PRNewswire/ --

A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies.

Therapies targeted to specific cancer-causing mutations may be the most promising strategy in cancer treatment. However, inter- and intra-tumor heterogeneity pose a significant challenge to maximizing therapeutic efficacy. Within a single patient, different cancer cells may have different sets of mutations making it very difficult to detect all of the relevant mutations in a single tissue biopsy.  

"To develop the right drug for the right patient, and to use those drugs most effectively, we need to understand the tumor burden in patients as fully as possible. Inostics' BEAMing technology may offer physicians a real-time composite picture of all the mutations across all tumors in any given patient using just a simple blood sample", George D. Demetri , M.D., Director of the Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Mass., said.

Demetri refers to data from a sub-analysis of the phase III GIST-Regorafenib in Progressive Desease (GRID) trial, designed to assess the efficacy of regorafenib in patients with GIST. Comparing conventional sequencing on tumor tissue with data generated using the BEAMing technology on blood samples they found resistance mutations 4 times more often in blood samples (48%) than in tumor tissue samples (12%). Furthermore, nearly half of the blood samples that had secondary KIT mutations harbored multiple secondary mutations.  "By using this technology we hope to develop the most rational drug combinations and better tests to match patients with the most effective therapies going forward", Demetri said.

BEAMing technology is a combination of digital PCR and flow cytometry originally developed by the group of Bert Vogelstein , M.D. at The Johns Hopkins University. Inostics licensed the technology and adopted it for routine use. Understanding the need of even more comprehensive coverage for the detection of de novo resistance mutations, Inostics is currently developing a sequencing based technology. "We are combining our expertise for highly sensitive mutation detection using BEAMing with the power of sequencing to hopefully detect all potential primary and secondary resistant mutations in the KIT gene in the near future" said Philipp Angenendt , Ph.D., Chief Technology Officer of Inostics.

BEAMing is the most sensitive and quantitative technology available today for the detection of tumor specific somatic mutations in blood samples. Inostics' BEAMing services are readily available to support clinical trials and research in oncology and have been successfully used on over 5000 samples in >34 clinical trials. Furthermore, Inostics offers BEAMing as a CLIA certified laboratory developed test for routine clinical analysis.

For more information on blood testing and the BEAMing Digital PCR technology refer to http://www.inostics.com or email us at info@inostics.com

Press contact:

Inostics
Friederike Lehmann , PhD
Marketing & Licensing
Phone +49-(0)40-413383-90
Fax +49-(0)40-413383-99
lehmann@inostics.com
http://www.inostics.com


'/>"/>
SOURCE Inostics GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
2. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
3. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
4. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
5. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Glooko Launches the Glooko™ IR Adapter to Give ACCU-CHEK® Blood Glucose Meter Customers Access to the Glooko Logbook Solution
8. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
9. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
10. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
11. Global Growth Factors (Blood And Tissue) Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Automation is one of the best ... growing demands for productivity in speed, accuracy, throughput and ... already adept of a wide range of functions that ... Instrumentation continues to evolve, and is poised to tackle ... years ago. Originally used mostly by the big pharmaceutical ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... In honor of National Physical Fitness and Sports ... who share their fitness journey on social media. , The foot care company, ... a $100 product voucher each week during May to one winner. , “Whether the ...
(Date:5/2/2016)... ... 02, 2016 , ... East Los Angeles dentist , Dr. Ramin Assili, ... Assili to receive any dental extraction treatment for $40 off the regular price. This ... With the lower price, patients can more easily afford extractions to eliminate teeth that ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist ... and cognitive decline. According to the research, which was published in the “Journal of ... cognitive decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a great time ... , “If you are ready to have a baby, it’s best to get ... Journal Babies is your Personal Conception & Pregnancy Organizer, written for women who plan ...
(Date:5/2/2016)... ... ... Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where he and ... Cities with the Highest Plastic Rates .” The other cities that made the list ... a survey by RealSelf and combining that data with the number of board-certified ...
Breaking Medicine News(10 mins):